S

    Shattuck Labs Inc (STTK)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.04
    -0.61 (-7.97%)

    Market Cap: $706.56M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    71%(17/24)
    Avg Surprise
    -5.25%
    Streak
    6 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.12
    Range$-0.21 - $-0.08
    9 analysts
    EPS RevisionsNo revisions (7d)
    1
    1
    30d
    EPS Estimate Drift
    90d ago$-0.12-5.5%
    60d ago$-0.13-11.8%
    30d ago$-0.12-6.9%
    7d ago$-0.12+0.0%
    Current$-0.12
    Revenue Consensus
    $0
    Range$0 - $0
    8 analysts
    Dec 31, 2026
    EPS Consensus$-0.11
    Range$-0.49 - $0.04
    10 analysts
    Revenue Consensus
    $122220
    Range$0 - $1M
    9 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.11---
    Sep 26EST
    		-$-0.12---
    Jun 26
    		$-0.12$-0.14+14.29%Beat+50.0%
    Mar 26
    		$-0.13$-0.13+0.00%Beat+51.9%
    Dec 25
    		$-0.12$-0.13+8.81%Beat+67.6%
    Sep 25
    		$-0.14$-0.15+6.67%Beat+57.6%
    Jun 25
    		$-0.24$-0.24+0.00%Beat+42.9%
    Mar 25
    		$-0.27$-0.28+4.42%Beat+27.0%
    Dec 24
    		$-0.37$-0.32-15.63%Miss+9.8%
    Sep 24
    		$-0.33$-0.42+21.43%Beat+49.2%
    Jun 24
    		$-0.42$-0.41-2.44%Miss+16.0%
    Mar 24
    		$-0.37$-0.45+17.78%Beat+24.5%
    Dec 23
    		$-0.41$-0.57+28.07%Beat+31.7%
    Sep 23
    		$-0.65$-0.52-25.00%Miss-12.1%
    Jun 23
    		$-0.50$-0.52+3.85%Beat+23.1%
    Mar 23
    		$-0.49$-0.63+22.22%Beat+15.5%
    Dec 22
    		$-0.60$-0.63+4.76%Beat-433.3%
    Sep 22
    		$-0.58$-0.67+13.43%Beat-41.5%
    Jun 22
    		$-0.65$-0.59-10.17%Miss-16.1%
    Mar 22
    		$-0.58$-0.50-16.00%Miss-107.1%
    Dec 21
    		$0.18N/A+141.86%Beat+158.1%
    Sep 21
    		$-0.41$-0.44+6.82%Beat+73.4%
    Jun 21
    		$-0.56$-0.35-60.00%Miss-55.5%
    Mar 21
    		$-0.28$-0.39+28.21%Beat-
    Dec 20
    		$-0.31$-0.39+20.51%Beat-
    Sep 20
    		$-1.54$-0.35-340.00%Miss-
    Jun 20
    		$-0.36$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-13.80EV/EBITDA-3.62x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-5570.00%
    ROE-39.20%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio27.59xQuick Ratio27.59x
    Trading Statistics
    Beta1.11Avg Volume874.94K
    52-Week High$8.3352-Week Low$0.98

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$7.58
    SMA 20$7.47
    SMA 50$7.01
    SMA 200$5.36
    EMA 10$7.54
    EMA 20$7.43
    EMA 50$7.03
    EMA 200$5.47

    MACD

    Line: 0.18Signal: 0.22Hist: -0.04

    ADX

    ADX: 24.7+DI: 23.6-DI: 25.3

    Aroon & PSAR

    Aroon Up88.0
    Aroon Down8.0
    PSAR$8.15

    Bollinger Bands

    Upper Band$8.06
    Lower Band$6.88
    %B Position1568%(Upper)
    Band Width0.13

    RSI (14-Day)

    Neutral
    45.8

    Momentum Oscillators

    Stoch %K49.2
    Stoch %D71.1
    Williams %R-91.0
    ROC (10d)-5.1%
    Momentum-0.38
    CCI (20d)-83.0
    MFI (14d)51.5

    Volatility Measures

    ATR (14d)$0.47(6.6%)
    StdDev (20d)0.29
    Hist Vol66.2%(High)

    Volume Flow

    VWAP$7.22
    OBV143.6M
    AD Line-11.9M
    CMF (20d)-0.025

    Volume Metrics

    Avg Vol (20d)895.3K
    Vol Ratio0.7x
    VWMA (20d)$7.50

    Pivot Points

    R3$8.14
    R2$8.04
    R1$7.84
    Pivot Point$7.74
    S1$7.54
    S2$7.44
    S3$7.24

    Advanced Oscillators

    TSI10.21
    Ultimate Osc41.6
    KST75.86

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$1.00M$0$0$34.70M$3.00M$1.61M$1.11M$714,000$686,000
    Cost of Revenue$0$0$906,000$0$0$0$20.21M$0$0$0$981,000$0
    Gross Profit$0$0$-906,000$1.00M$0$0$14.49M$3.00M$1.61M$1.11M$714,000$686,000
    Operating Expenses$16.16M$15.54M$13.37M$11.72M$13.03M$14.39M$19.64M$20.92M$24.57M$21.16M$19.66M$29.28M
    R&D$11.70M$10.95M$9.06M$7.62M$8.68M$9.92M$15.39M$16.31M$19.24M$16.26M$15.23M$24.21M
    SG&A$4.46M$4.60M$4.32M$4.10M$4.35M$4.47M$4.25M$4.60M$5.33M$4.89M$4.44M$5.07M
    Operating Income$-16,155,000$-15,545,000$-13,371,000$-10,716,000$-13,032,000$-14,389,000$-19,641,000$-17,920,000$-22,962,000$-20,044,000$-18,951,000$-28,598,000
    Interest Income$1.03M$779,000$0$0$804,000$689,000$0$0$0$0$0$0
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-15,152,000$-14,767,000$-12,593,000$-10,056,000$-12,458,000$-13,702,000$-18,679,000$-16,675,000$-21,552,000$-18,504,000$-17,687,000$-27,541,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-15,152,000$-14,767,000$-12,593,000$-10,056,000$-12,458,000$-13,702,000$-18,679,000$-16,675,000$-21,552,000$-18,504,000$-17,687,000$-27,541,000
    EBITDA$-15,525,000$-14,703,000$-14,676,000$-9,305,000$-12,332,000$-13,457,000$-23,334,000$-16,464,000$-21,207,000$-17,901,000$-21,803,000$-27,072,000
    EBIT$-16,181,000$-15,546,000$-15,296,000$-10,056,000$-13,262,000$-14,391,000$-23,853,000$-16,675,000$-21,552,000$-18,504,000$-22,356,000$-27,541,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about STTK

    News

    Raymond James Initiates Shattuck Labs(STTK.US) With Buy Rating, Announces Target Price $18

    Raymond James has initiated coverage on Shattuck Labs (STTK.US) with a "Buy" rating. The firm has set a target price of $18 for the company's stock. This new coverage suggests a positive outlook from Raymond James on Shattuck Labs' future performance.

    Moomoo•8/25/26•
    Bullish

    STTK Initiated Coverage by Raymond James -- Rating Set to Strong Buy

    Raymond James has initiated coverage on Shattuck Labs (STTK) with a "Strong Buy" rating and an $18.00 price target, despite the stock being significantly overvalued according to GuruFocus's GF Value™. The company, which operates in the biotechnology sector developing treatments for inflammatory and immune-mediated diseases, has a low GF Score™ of 42/100, primarily due to low profitability, but shows some financial strength. Insider activity indicates mixed sentiment, with more selling than buying over the last three months.

    GuruFocus•8/24/26•
    Neutral

    Raymond James initiates Shattuck Labs stock with strong buy rating

    Raymond James initiated coverage on Shattuck Labs Inc. (NASDAQ:STTK) with a Strong Buy rating and a $18.00 price target, citing the potential of its drug candidate SL-325 in the ulcerative colitis and Crohn's disease market. Despite the stock's significant return over the past year, InvestingPro data suggests it may be overvalued. Other recent news includes a public offering by Shattuck Labs and revised price targets from H.C. Wainwright and JPMorgan.

    Investing.com•8/24/26•
    Bullish

    Raymond James Initiates Coverage on Shattuck Labs With Strong Buy Rating, $18 Price Target

    Raymond James has initiated coverage on Shattuck Labs (STTK) with a "Strong Buy" rating and an $18 price target. The biotechnology company focuses on developing treatments for inflammatory and immune-mediated diseases, with its lead product candidate, SL-325, currently in Phase I clinical trials. Shattuck Labs also reported its Q2 and H1 2026 earnings results on August 11.

    marketscreener.com•8/24/26•
    Bullish

    Shattuck Labs, Inc. (STTK) is a Great Momentum Stock: Should You Buy?

    Shattuck Labs, Inc. (STTK) is identified as a strong momentum stock with a Zacks Momentum Style Score of A and a Zacks Rank of #2 (Buy). The article highlights its impressive short-term and long-term price performance, significantly outperforming its industry and the S&P 500. Positive earnings estimate revisions further support its promising outlook for investors seeking near-term growth.

    Yahoo Finance•8/20/26•
    Bullish

    Frequently Asked Questions About STTK

    Does STTK pay dividends?
    Shattuck Labs Inc (STTK) does not currently pay a regular dividend.
    What is STTK's market cap?
    Shattuck Labs Inc (STTK) has a market capitalization of $706.56M with a current stock price of $7.04.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In